TransMedics Group falls after tightening annual revenue forecast range, names new CFO

** Medtech company TransMedics Group's TMDX shares fall 10.72% to $76.01 after market

** Company forecasts full-year revenue to be between $428 mln and $432 mln, vs prior range of $425 mln to $445 mln

** Analysts expect 2024 revenue of $432.36 mln, according to data compiled by LSEG

** Company names Gerardo Hernandez as chief financial officer, succeeding Stephen Gordon

** Hernandez most recently served as vice president finance, head of corporate financial planning and analysis at Alnylam Pharmaceuticals ALNY

** As of last close, TransMedics shares up ~8% YTD